Your browser doesn't support javascript.
loading
The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa, Ricardo; Carneiro, Benedito A; Tavora, Fabio; Pai, Sachin G; Kaplan, Jason B; Chae, Young Kwang; Chandra, Sunandana; Kopp, Peter A; Giles, Francis J.
Afiliação
  • Costa R; Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Carneiro BA; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Tavora F; Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Pai SG; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Kaplan JB; Department of Pathology, Messejana Heart and Lung Hospital, Fortaleza, Brazil.
  • Chae YK; Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Chandra S; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Kopp PA; Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Giles FJ; Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Oncotarget ; 7(29): 46734-46749, 2016 Jul 19.
Article em En | MEDLINE | ID: mdl-27102148
Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such as melanoma, among others. However, these advances have not brought meaningful benefits for patients with ACC. Extensive genomic analyses of ACC have revealed numerous signal transduction pathway aberrations (e.g., insulin growth factor receptor and Wnt/ß-catenin pathways) that play a central role in pathophysiology. These molecular alterations have been explored as potential therapeutic targets for drug development. This manuscript summarizes recent discoveries in ACC biology, reviews the results of early clinical studies with targeted therapies, and provides the rationale for emerging treatment strategies such as immunotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Córtex Suprarrenal / Carcinoma Adrenocortical Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Córtex Suprarrenal / Carcinoma Adrenocortical Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos